Ken Griffin Aveo Pharmaceuticals, Inc. Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$8.48 - $14.97 $2.33 Million - $4.11 Million	274,675 Added 673.19%	315,477 $4.72 Million
Q3 2022 Nov 14, 2022	BUY	$6.61 - $8.72 $269,701 - $355,793	40,802 New	40,802 $336,000
Q4 2021 Feb 14, 2022	BUY	$4.69 - $7.4 $302,467 - $477,240	64,492 Added 134.77%	112,347 $526,000
Q3 2021 Nov 15, 2021	BUY	$5.12 - $6.89 $81,336 - $109,454	15,886 Added 49.69%	47,855 $295,000
Q1 2021 May 17, 2021	SELL	$5.97 - $15.28 $1,152 - $2,949	-193 Reduced 0.6%	31,969 $234,000
Q4 2020 Feb 16, 2021	SELL	$5.08 - $6.68 $34,361 - $45,183	-6,764 Reduced 17.38%	32,162 $186,000
Q3 2020 Nov 16, 2020	SELL	$4.16 - $6.26 $1.5 Million - $2.26 Million	-361,077 Reduced 90.27%	38,926 $231,000
Q2 2020 Aug 14, 2020	BUY	$3.47 - $9.99 $1.33 Million - $3.83 Million	383,720 Added 2356.57%	400,003 $2.06 Million
Q1 2020 May 15, 2020	BUY	$2.6 - $6.9 $42,335 - $112,352	16,283 New	16,283 $59,000

Ticker AVEO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,676,000
Description
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.